P1264 Metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with Inflammatory Bowel Disease (IBD). A prospective single-center study

Le résumé fourni par la source

Abstract Background Inflammatory bowel disease (IBD) has been linked to an increased risk of metabolic dysfunction-associated steatotic liver disease (MASLD). This study assesses MASLD prevalence in IBD patients and its associations with demographic, clinical, and laboratory features. Methods This prospective study included 113 adult IBD outpatients [Crohn’s disease (CD): 63, ulcerative colitis (UC): 49, unclassified colitis: 1; male/female: 68/45; mean age: 47.8 years (SD: 15.06); mean age at IBD diagnosis: 35.84 years (SD: 15.57)] derived from the Gastroenterology Division, University Hospital of Patras, Greece. Of these, 95 patients underwent ultrasound, clinical evaluation, and laboratory testing to diagnose MASLD. Results Among the 95 patients evaluated, 22 (23.2%) were diagnosed with MASLD, 8 (9.4%) with alcoholic liver disease (ALD), and 65 (68.4%) had no steatotic liver disease (No-SLD). MASLD patients were predominantly male (n = 11), with a CD to UC ratio of 16:6, a mean age of 46.4 years (SD:10.80), and a mean IBD diagnosis age 34.82 years (SD:14.20). Patients with MASLD had significantly increased rates of central obesity (p = 0.001, OR = 5.90, CI: 2.10-16.58), overall obesity (p = 0.001, OR = 4.2, CI:1.15-15.22), higher body mass index (BMI) (p = 0.001, OR-1.25, CI:1.10-1.42), elevated SGOT (p=0.019, OR=1.06, CI=1.01-1.117), SGPT (p=0,027, OR=1.03, CI=1.003-1.059), and greater waist circumference (p=0.04, OR=1.05, CI:1.01-1.09) compared to non-MASLD patients. No significant differences were observed between groups regarding age (p = 0.787), age at IBD diagnosis (p = 0.723), sex distribution (p = 0.277), disease type (p = 0.312), smoking status (p = 0.335), γ-GT (p = 0.896) and ALP (p = 0.440). Lastly, no significant differences were found regarding IBD clinical activity markers (CDAI, p = 0.698; Trulove-Witts, p = 0.764), CRP (p=0.798), IBD-related surgery(p=0.734), or extraintestinal manifestations(p=0.059). Conclusion MASLD is prevalent among IBD patients and is significantly associated with central and overall obesity, increased BMI, liver enzymes, and waist circumference. These findings suggest MASLD could be an early indicator of metabolic syndrome in IBD patients, preceding other cardiometabolic disorders. Further research is needed to clarify the relationship between MASLD and IBD and guide early intervention strategies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.